fatnews.com Home page  >  Article | Previous article | Next article

SEARCH

QUICKLINKS AND VIEW OPITONS

  • Categories of Articles
  • Summary View
  • Headline View
  • Archive of Quotes
  • Contact Us
  • Follow @fatnews

    Low-dose Qnexa: 3.75 mg Phentermine plus 23 mg Topamax causes weight loss of 5.1% vs 1.6% w/placebo


    Posted by .(JavaScript must be enabled to view this email address)
    Wednesday, September 09, 2009 11:12 am Email this article
    Morbidly obese patients given the lowest dose of Qnexa, containing 3.75 mg of phentermine plus 23 mg of Topamax (topiramate), lost an average weight loss of 18 pounds versus 6 pounds with placebo after one year, or 5.1 percent of body weight versus 1.6 percent with placebo according to a press release from press release from Vivus, Inc, the company developing the drug. Weight Loss for Those Who Completed the Study

    Weight Loss for Those Who Completed the Study : 7% vs 2.5%

    Forty-seven percent (47 percent) of those given the low-dose Qnexa completed the entire one-year study.

    The average weight loss for these patients was 7 percent of body weight versus 2.5 percent of those given the placebo who completed the study.

     

    Subjects

    Subjects: 1267 morbidly obese patients

    The study, which was called the EQUIP (OB-302) study, involved “1,267 morbidly obese patients (1,050 females and 217 males) across 93 centers in the United States” the press release notes.

    The number on each dose of the drug was as follows:

     

    BMI

    Starting BMI: 42

    The average starting body mass index (BMI) was 42.1.

     

    Dose

    Dose slowly increased over one month

    The dose was slowly increased (titrated) over four weeks.

     

    Diet

    Diet: Patients suggested to reduce calorie intake by 500 calories per day

    Patients were asked to follow a diet that was reduced by 500 calories per day.

     

    Conclusion

    Conclusion: Weight loss with drug combination exceeds other agents

    “The weight loss observed with Qnexa in these two one-year, double-blind, randomized trials far exceeds the weight loss observed for other agents reported in literature,” said Kishore Gadde, MD, director of obesity clinical trials at Duke University and a lead investigator.

    REFERENCE

    Vivus. Vivus announces positive results from two phase 3 studies; obese patients on qnexa achieve average weight loss up to 14.7% and significant improvements in co-morbidities. Press Release from Vivus Inc. 2009 Sept 09, http://ir.vivus.com/releasedetail.cfm?ReleaseID=407933

    Articles on the same subject can be found here:


    COMMENTS

    Please feel free to share your comments about this article.


    Name:

    Email:

    Comments:

    Please enter the word you see in the image below:


    Remember my personal information

    Notify me of follow-up comments?



    © Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.